Inozyme Pharma Net Cash Flow 2020-2025 | INZY

Inozyme Pharma net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Inozyme Pharma Net Cash Flow 2020-2025 | INZY

Inozyme Pharma net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.6B
Amgen (AMGN)$164.4B
Gilead Sciences (GILD)$137B
Vertex Pharmaceuticals (VRTX)$120.7B
Bristol Myers Squibb (BMY)$97.7B
CSL (CSLLY)$84.2B
GSK (GSK)$75.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$42.4B
Argenex SE (ARGX)$35B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$20.3B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$16.2B
Genmab (GMAB)$14B
Genmab (GNMSF)$13.8B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.7B
Exelixis (EXEL)$12.1B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.1B
Exact Sciences (EXAS)$9.4B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.8B